Financial reports
ARS
2023 FY
Annual report to shareholders
29 Apr 24
10-K
2023 FY
Annual report
27 Feb 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
5 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
4 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
6 May 22
Current reports
8-K
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
29 Mar 24
8-K
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
26 Feb 24
8-K
Other Events
13 Feb 24
8-K
Departure of Directors or Certain Officers
13 Dec 23
8-K
Other Events
2 Oct 23
8-K
Entry into a Material Definitive Agreement
15 Sep 23
8-K
Entry into a Material Definitive Agreement
12 Sep 23
8-K
Regulation FD Disclosure
12 Sep 23
8-K
Submission of Matters to a Vote of Security Holders
23 Jun 23
8-K
Departure of Directors or Certain Officers
4 Apr 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
20 Sep 23
424B5
Prospectus supplement for primary offering
13 Sep 23
424B5
Prospectus supplement for primary offering
12 Sep 23
POS AM
Prospectus update (post-effective amendment)
5 Apr 23
8-A12B
Registration of securities on exchange
23 Feb 23
S-8
Registration of securities for employees
20 Dec 22
424B3
Prospectus supplement
31 Oct 22
S-4
Registration of securities issued in business combination transactions
13 Oct 22
424B5
Prospectus supplement for primary offering
4 Oct 22
Proxies
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
PRE 14A
Preliminary proxy
17 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEF 14A
Definitive proxy
30 Apr 21
PX14A6G
Letter to shareholders
29 May 20
Other
EFFECT
Notice of effectiveness
9 May 23
CERT
Certification of approval for exchange listing
24 Feb 23
EFFECT
Notice of effectiveness
1 Nov 22
CORRESP
Correspondence with SEC
27 Oct 22
UPLOAD
Letter from SEC
19 Oct 22
UPLOAD
Letter from SEC
18 Oct 21
CORRESP
Correspondence with SEC
7 Oct 21
UPLOAD
Letter from SEC
27 Sep 21
EFFECT
Notice of effectiveness
13 Sep 21
CORRESP
Correspondence with SEC
8 Sep 21
Ownership
4
John Militello
24 Apr 24
144
Notice of proposed sale of securities
22 Apr 24
4
DAVID P SOUTHWELL
16 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
144
Notice of proposed sale of securities
12 Apr 24
4
Mark Andrew White
10 Apr 24
144
Notice of proposed sale of securities
8 Apr 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
5 Apr 24
3
Jonathan David Schwartz
3 Apr 24
4
Aaron Ondrey
3 Apr 24